STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Julie R. Park, Jason Wendler et al.|Journal of Clinical Oncology|2024Cited by 46
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.Navin Pinto, Julie R. Park, Catherine M. Albert et al.|Journal of Clinical Oncology|2022Cited by 27
STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.Catherine M. Albert, Julie R. Park, Navin Pinto et al.|Journal of Clinical Oncology|2022Cited by 17
Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysisMallory Taylor, Jennifer M. Knight, Steve W. Cole et al.|Blood Advances|2023Cited by 12
ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.Catherine M. Albert, Julie R. Park, Navin Pinto et al.|Journal of Clinical Oncology|2023Cited by 6